Danish manufacturer of weight-loss and diabetes drugs under pressure from US rival Eli Lilly
The Danish maker of the weight-loss and diabetes drugs Wegovy and Ozempic is to cut 9,000 jobs as it slashed its profit forecast again, amid fierce competition from its US rival Eli Lilly.
Novo Nordisk’s decision to cut 11% of its global workforce of 78,400 is an attempt by the new chief executive, Mike Doustdar, to revive its fortunes.
Continue reading...
0 Comments